Importantly, metabolic reprogramming of glycolysis in AML is often connected to oncogenic signaling pathways, such as those activated by FLT3-ITD mutations, which can upregulate glycolytic flux independently of oxygen availability [94]. The gene discussed is FLT3; the disease is acute myeloid leukemia.